393 related articles for article (PubMed ID: 25843712)
1. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.
Blakely CM; Pazarentzos E; Olivas V; Asthana S; Yan JJ; Tan I; Hrustanovic G; Chan E; Lin L; Neel DS; Newton W; Bobb KL; Fouts TR; Meshulam J; Gubens MA; Jablons DM; Johnson JR; Bandyopadhyay S; Krogan NJ; Bivona TG
Cell Rep; 2015 Apr; 11(1):98-110. PubMed ID: 25843712
[TBL] [Abstract][Full Text] [Related]
2. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
[TBL] [Abstract][Full Text] [Related]
3. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
4. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y
Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitination profiling identifies sensitivity factors for IAP antagonist treatment.
Varfolomeev E; Izrael-Tomasevic A; Yu K; Bustos D; Goncharov T; Belmont LD; Masselot A; Bakalarski CE; Kirkpatrick DS; Vucic D
Biochem J; 2015 Feb; 466(1):45-54. PubMed ID: 25423073
[TBL] [Abstract][Full Text] [Related]
6. TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways.
Zhang L; Dittmer MR; Blackwell K; Workman LM; Hostager B; Habelhah H
Cell Signal; 2015 Feb; 27(2):306-14. PubMed ID: 25446254
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
8. PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Ni J; Zhou LL; Ding L; Zhao X; Cao H; Fan F; Li H; Lou R; Du Y; Dong S; Liu S; Wang Z; Ma R; Wu J; Feng J
Exp Cell Res; 2017 Dec; 361(2):246-256. PubMed ID: 29080795
[TBL] [Abstract][Full Text] [Related]
9. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
10. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
[TBL] [Abstract][Full Text] [Related]
11. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
Bivona TG; Hieronymus H; Parker J; Chang K; Taron M; Rosell R; Moonsamy P; Dahlman K; Miller VA; Costa C; Hannon G; Sawyers CL
Nature; 2011 Mar; 471(7339):523-6. PubMed ID: 21430781
[TBL] [Abstract][Full Text] [Related]
12. Triptolide reverses the Taxol resistance of lung adenocarcinoma by inhibiting the NF-κB signaling pathway and the expression of NF-κB-regulated drug-resistant genes.
Jiang N; Dong XP; Zhang SL; You QY; Jiang XT; Zhao XG
Mol Med Rep; 2016 Jan; 13(1):153-9. PubMed ID: 26531258
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
14. 4',6-Dihydroxy-4-methoxyisoaurone inhibits TNF-α-induced NF-κB activation and expressions of NF-κB-regulated target gene products.
Ma J; Mi C; Wang KS; Lee JJ; Jin X
J Pharmacol Sci; 2016 Feb; 130(2):43-50. PubMed ID: 26654829
[TBL] [Abstract][Full Text] [Related]
15. TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Nan J; Du Y; Chen X; Bai Q; Wang Y; Zhang X; Zhu N; Zhang J; Hou J; Wang Q; Yang J
Mol Cancer Ther; 2014 Mar; 13(3):617-29. PubMed ID: 24401319
[TBL] [Abstract][Full Text] [Related]
16. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
17. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
[TBL] [Abstract][Full Text] [Related]
18. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway.
Li Y; Deng L; Zhao X; Li B; Ren D; Yu L; Pan H; Gong Q; Song L; Zhou X; Dai T
J Pathol; 2018 Nov; 246(3):366-378. PubMed ID: 30043491
[TBL] [Abstract][Full Text] [Related]
19. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.
Mongre RK; Sodhi SS; Sharma N; Ghosh M; Kim JH; Kim N; Park YH; Shin YG; Kim SJ; Jiao ZJ; Huynh do L; Jeong DK
Int J Oncol; 2016 Jan; 48(1):84-98. PubMed ID: 26573874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]